Clinical and Experimental Pediatrics

The Korean Pediatric Society (대한소아청소년과학회)
권호 표지

Clinical significance of acanthosis nigricans in children and adolescents with obesity induced metabolic complications

비만으로 인한 대사적 합병증을 가진 소아 및 청소년에서 흑색가시세포증의 임상적 의의

  • Chueh, Hee Won (Department of Pediatrics, College of Medicine, Dong-A University) ;
  • Cho, Gyu Rang (Department of Pediatrics, College of Medicine, Dong-A University) ;
  • Yoo, Jaeho (Medical Sciences Research Institute College of Medicine, Dong-A University)
  • 최희원 (동아대학교 의과대학 소아과학교실) ;
  • 조규랑 (동아대학교 의과대학 소아과학교실) ;
  • 유재호 (동아대학교 의과대학 의과학연구원)
  • Received : 2007.07.20
  • Accepted : 2007.08.16
  • Published : 2007.10.15
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose : This study investigated the clinical significance of AN in children and adolescents with obesity induced metabolic complications. Methods : Forty-nine patients who had obesity induced metabolic complications were participated in this cross-sectional study. Obesity induced metabolic complications are as follows: hypertension, dyslipidemia, impaired fasting glucose (IFG), impaired glucose tolerance (IGT), nonalcoholic steatohepatitis (NASH), homeostasis model assessment of insulin resistance (HOMA-IR)>3.16. Clinical characteristics, such as, age, percentage-weight-for-height (PWH), pubertal status, blood pressure (BP), fasting plasma insulin level, fasting and post-oral glucose tolerance test 2-hour glucose levels, liver function test, lipid profile, HOMA-IR were compared according to the presence of AN. Results : Sixty-five percent of patients had AN, 57.1% NASH, 57.1% dyslipidemia, 55.1% hypertension, 46.9% IFG, 24.5% HOMA-IR>3.16 and 16.2% IGT. The patients who were moderately to severely obese with AN had higher incidence of IGT and HOMA-IR>3.16. The patients with AN had significantly higher diastolic BP ($79.4{\pm}6.9$ vs $75.4{\pm}5.6mmHg$), fasting levels of plasma insulin ($10.6{\pm}6.0$ vs $6.2{\pm}5.4{\mu}IU/mL$), HOMA-IR index ($2.6{\pm}1.4$ vs $1.4{\pm}1.3$) and PWH ($42.4{\pm}13.0$ vs $34.3{\pm}1.8%$). The increasing tendency for the presence of AN was significantly related to the cumulative number of obesity induced metabolic complications. Binary logistic regression analysis revealed that the presence of AN was significantly associated with fasting plasma insulin level, PWH and IFG. Conclusion : AN could be useful as a clinical surrogate of obesity induced metabolic complications.

목 적 : 본 연구는 비만으로 인한 대사적 합병증을 가진 소아 및 청소년에서 흑색가시세포증이 어떤 임상적 의의를 가지는지 알아보고자 하였다. 방 법 : 동아대학교의료원 소아청소년과에서 한개 이상의 비만으로 인한 대사적 합병증으로 진료 받았던 49명의 소아 및 청소년들을 대상으로 하였다. 비만으로 인한 대사적 합병증은 고혈압, 이상지질혈증, 공복혈당장애, 내당능장애, 비알콜성지방간염, HOMA-IR 값이 3.16 이상으로 인슐린 저항성이 있는 경우로 정의하였다. 나이, 비만도, 사춘기 발달 상태, 혈압, 공복 혈장 인슐린, 공복 혈장 포도당, 경구당부하검사 2시간 후 혈장 포도당, 간기능 검사, 혈장 지질 검사, HOMA-IR 값을 흑색가시세포증의 유무에 따라 비교 분석하였다. 결 과 : 32(65.3%)명에서 흑색가시세포증이 관찰되었다. 28 (57.1%)명의 환아에서 비알콜성지방간염이 관찰되었으며, 이상지질혈증은 28명(57.1%), 고혈압은 27명(55.1%), 공복혈당장애는 23명(46.9%), 내당능장애는 6명(16.2%)에서 관찰되었다. HOMA-IR 값이 3.16 이상으로 인슐린 저항성을 가진 환아는 12명(24.5 %)에서 관찰되었다. 내당능장애와 HOMA-IR 값이 3.16 이상인 인슐린 저항성은 흑색가시세포증을 동반한 중등도 이상의 비만군에서 의미있게 발생 빈도가 증가되었다(P<0.05, P<0.05). 비만도는 흑색가시세포증이 있는 환아에서 $42.4{\pm}13.0%$로 흑색가시세포증이 없는 환아의 $34.3{\pm}1.8%$ 보다 높았다(P<0.05). 흑색가시세포증이 동반된 환아에서 확장기 혈압이 높았으며($79.4{\pm}6.9mmHg$ vs $75.4{\pm}5.6mmHg$, P<0.05), 공복 인슐린($10.6{\pm}6.0{\mu}IU/mL$ vs $6.2{\pm}5.4{\mu}IU/mL$, P<0.01)은 증가되어 있었다. 흑색가시세포증이 동반된 환아에서 HOMA-IR 값($2.6{\pm}1.4$ vs $1.4{\pm}1.3$, P<0.01)이 높았으며, QUICKI 값($0.61{\pm}0.14$ vs $0.81{\pm}0.27$, P<0.01)은 낮았다. 비만으로 인한 대사적 합병증을 많이 가지고 있을수록 흑색가시세포증의 발현 빈도가 증가되었다(P< 0.01). 비만으로 인한 대사적 합병증이 동반된 환아에서 흑색가시세포증의 발생 위험인자를 평가하기 위해 시행한 binary logistic regression model에서 비만도와 공복 혈장 인슐린이 높을수록, 공복혈당장애가 있을 경우 흑색가시세포증의 발생 위험이 증가하였다. 결 론 : 흑색가시세포증은 비만으로 인한 대사적 합병증을 조기에 진단할 수 있는 임상적인 지표로써 유용하게 사용되어질 수 있을 것으로 생각된다.

Keywords

Acknowledgement

Supported by : 동아대학교

References

  1. Park YS, Lee DH, Choi JM, Kang YJ, Kim CH. Trend of obesity in school age children in Seoul over the past 23 years. Korean J Pediatr 2004;47:247-57
  2. Freedman DS, Khan LK, Dietz WH, Srinivasan SR, Berenson GS. Relationship of childhood obesity to coronary heart disease risk factors in adulthood: The Bogalusa Heart Study. Pediatrics 2001;108:712-8 https://doi.org/10.1542/peds.108.3.712
  3. Steinberger J, Moorehead C, Katch V, Rocchini AP. Relationship between insulin resistance and abnormal lipid profile in obese adolescents. J Pediatr 1995;126:690-5 https://doi.org/10.1016/S0022-3476(95)70394-2
  4. Cook S, Weitzman M, Auinger P, Nguyen M, Dietz WH. Prevalence of a metabolic syndrome phenotype in adolescents: findings from the third National Health and Nutrition Examination Survey, 1988-1994. Arch Pediatr Adolesc Med 2003;157:821-7 https://doi.org/10.1001/archpedi.157.8.821
  5. Schwimmer JB, Deutsch R, Rauch JB, Behling C, Newbury R, Lavine JE. Obesity, insulin resistance, and other clinicopathological correlates of pediatric nonalcoholic fatty liver disease. J Pediatr 2003;143:500-5 https://doi.org/10.1067/S0022-3476(03)00325-1
  6. Yosipovitch G, DeVore A, Dawn A. Obesity and the skin: skin physiology and skin manifestations of obesity. J Am Acad Dermatol 2007:56:901-16 https://doi.org/10.1016/j.jaad.2006.12.004
  7. Kahn CR, Flier JS, Bar RS, Archer JA, Gorden P, Martin MM, et al. The syndromes of insulin resistance and acanthosis nigricans. Insulin-receptor disorders in man. N Engl J Med 1976;294:739-45 https://doi.org/10.1056/NEJM197604012941401
  8. Stuart CA, Smith MM, Gilkison CR, Shaheb S, Stahn RM. Acanthosis nigricans among native Americans: an indicator of high diabetes risk. Am J Public Health 1994;84:1839-42 https://doi.org/10.2105/AJPH.84.11.1839
  9. Mukhtar Q, Cleverley G, Voorhees RE, McGrath JW. Prevalence of acanthosis nigricans and its association with hy perinsulinemia in New Mexico adolescents. J Adolesc Health 2001 ;28:372-6 https://doi.org/10.1016/S1054-139X(00)00217-2
  10. Kobaissi HA, Weigensberg MJ, Ball GD, Cruz ML, Shaibi GQ, Goran MI. Relation between acanthosis nigricans and insulin sensitivity in overweight Hispanic children at risk for type 2 diabetes. Diabetes Care. 2004;27:1412-6 https://doi.org/10.2337/diacare.27.6.1412
  11. Copeland K, Pankratz K, Cathey V, Immohotichey P, Maddox J, Felton B, et al. Acanthosis nigricans, insulin resistance (HOMA) and dyslipidemia among native American children. J Okla State Med Assoc 2006;99:19-24
  12. Hardin DS. Screening for type 2 diabetes in children with acanthosis nigricans. Diabetes Educ 2006;32:547-52 https://doi.org/10.1177/0145721706290436
  13. Lee JK. Standard blood pressure value in Korean children and adolescents, Program and Abstract, the 56th Annual Spring Meeting of the Korean Pediatric Society; 2006 April 28-29; Youngpyung. Seoul: The Korean Pediatric Society, 2006
  14. Keskin M, Kurtoglu S, Kendirci M, Atabek ME, Yazici C. Homeostasis model assessment is more reliable than the fasting glucose/insulin ratio and quantitative insulin sensitivity check index for assessing insulin resistance among obese children and adolescents. Pediatrics 2005;115:e500-3 https://doi.org/10.1542/peds.2004-1921
  15. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003;26:3160-7 https://doi.org/10.2337/diacare.26.11.3160
  16. American Academy of Pediatrics. Committee on Nutrition. Cholesterol in childhood. Pediatrics 1998;101:141-7 https://doi.org/10.1542/peds.101.1.141
  17. Dunaif A, Green G, Phelps RG, Lebwohl M, Futterweit W, Lewy L. Acanthosis nigricans, insulin action, and hyperandrogenism: clinical, histological, and biochemical findings. J Clin Endocrinol Metab 1991;73:590-5 https://doi.org/10.1210/jcem-73-3-590
  18. Rendon MI, Cruz PD, Sontheimer RD, Bergstresser PR. Acanthosis nigricans: a cutaneous marker of tissue resistance to insulin. J Am Acad Dermatol 1989;21:461-9 https://doi.org/10.1016/S0190-9622(89)70208-5
  19. Cruz PD, Hud JA. Excess insulin binding to insulin-like growth factor receptors: proposed mechanism for acanthosis nigricans. J Invest Dermatol 1992;98(6 Suppl):82S-85S https://doi.org/10.1111/1523-1747.ep12462293
  20. Hermanns-Le T, Scheen A, Pierard GE. Acanthosis nigricans associated with insulin resistance : pathophysiology and management. Am J Clin Dermatol 2004;5:199-203 https://doi.org/10.2165/00128071-200405030-00008
  21. Stuart CA, Pate CJ, Peters EJ. Prevalence of acanthosis nigricans in an unselected population. Am J Med 1989;87: 269-72 https://doi.org/10.1016/S0002-9343(89)80149-4
  22. Stuart CA, Driscoll MS, Lundquist KF, Gilkison CR, Shaheb S, Smith MM. Acanthosis nigricans. J Basic Clin Physiol Pharmacol 1998;9:407-18
  23. Yamazaki H, Ito S, Yoshida H. Acanthosis nigricans is a reliable cutaneous marker of insulin resistance in obese Japanese children. Pediatr Int 2003:45:701-5 https://doi.org/10.1111/j.1442-200X.2003.01812.x
  24. Hud JA, Cohen JB, Wagner JM, Cruz PD. Prevalence and significance of acanthosis nigricans in an adult obese population. Arch Dermatol 1992;128:941-4 https://doi.org/10.1001/archderm.128.7.941
  25. Stuart CA, Peters EJ, Prince MJ, Richards G, Cavallo A, Meyer WJ 3rd. Insulin resistance with acanthosis nigricans: the roles of obesity and androgen excess. Metabolism 1986; 35:197-205 https://doi.org/10.1016/0026-0495(86)90201-5
  26. Burke JP, Hale DE, Hazuda HP, Stern MP. A quantitative scale of acanthosis nigricans. Diabetes Care 1999;22:1655-9 https://doi.org/10.2337/diacare.22.10.1655
  27. Stoddart ML, Blevins KS, Lee ET, Wang W, Blackett PR. Association of acanthosis nigricans with hyperinsulinemia compared with other selected risk factors for type 2 diabetes in Cherokee Indians: the Cherokee Diabetes Study. Diabetes Care 2002;25:1009-14 https://doi.org/10.2337/diacare.25.6.1009
  28. Nguyen TT, Keil MF, Russell DL, Pathomvanich A, Uwaifo GI, Sebring NG, et al. Relation of acanthosis nigricans to hyperinsulinemia and insulin sensitivity in overweight African American and white children. J Pediatr 2001;138:474-80 https://doi.org/10.1067/mpd.2001.112657
  29. Lee SY, Shin CH, Yang SW. Clinical characteristics of type 2 diabetes in children and adolescents. J Korean Pediatr Soc 2002:45:754 -63
  30. Choi JG, Ko JM, Lee JH, Choi JH, Yoo HW. Clinical characteristics of type 2 diabetes in children and adolescents. J Korea Soc Pediatr Endocrinol 2006;11:64-9
  31. Hwang SW, Kim DH, Kim HS. Prevalence of the nonalcoholic fatty liver disease in obese children. Korean J Pediatr 2005:48:13-20
  32. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002;346:1221-31 https://doi.org/10.1056/NEJMra011775
  33. Kim HM, Park J, Kim HS, Kim DH, Park SH. Obesity and cardiovascular risk factors in Korean children and adolescents aged 10-18 years from the Korean National Health and Nutrition Examination Survey, 1998 and 2001. Am J Epidemiol 2006;164:787-93 https://doi.org/10.1093/aje/kwj251
  34. Uwaifo GI, Tjahjana M, Freedman RJ, Lutchman G, Promrat K. Acanthosis nigricans in patients with nonalcoholic stea tohepatitis: an uncommon finding. Endocr Pract 2006;12:371-9 https://doi.org/10.4158/EP.12.4.371